Industry: Psychosis diagnostics
For the 6.5 million Americans who experience serious psychiatric conditions such as psychosis, diagnosis is still performed without addressing underlying biological mechanisms. B-SNIP’s technology, emerging from a lab at the University of Georgia, seeks to improve the diagnosis of psychosis via a database composed of symptoms, brain function and molecular data.
With the B-SNIP Diagnostics database, patients can be labeled with a biotype based on the findings of the team’s research, which can greatly improve the accuracy of treatment plans.
Seven out of 10 patients currently diagnosed with a kind of psychosis are not treated successfully, highlighting the need for more accurate diagnostic procedures in the field.
Company website: B-SNIP Diagnostics